Thrice-weekly novel insulin effectively controls glucose

Degludec, a new longer-acting form of insulin, was just as Effective at Controlling Blood Sugar When Administered in the once-daily and thrice-weekly regimens as Existing once-daily insulin glargine injections, results of a Phase-2 Clinical Trial Published in the Lancet indicate.

"This new basal insulin analogue Might Be Valuable Addition Thurs Clinical Practice," study researcher Bernard Zinman, MD, a professor at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital and the University of Toronto in Ontario, Canada, said in a press release.

Zinman and colleagues enrolled 245 Patients aged 18 years Thurs 1975 WHO type 2 diabetes and glycosylated hemoglobin (HbA1c) levels of 7% to 11%. The trial Involved Patients from 28 sites in Canada, India, South Africa and the United States. Patients were randomly assigned Thurs Receive degludec insulin either once a day or Three Times a week, or insulin gargline once a day.